Cargando…
Evolution of kinase polypharmacology across HSP90 drug discovery
Most small molecules interact with several target proteins but this polypharmacology is seldom comprehensively investigated or explicitly exploited during drug discovery. Here, we use computational and experimental methods to identify and systematically characterize the kinase cross-pharmacology of...
Autores principales: | Antolin, Albert A., Clarke, Paul A., Collins, Ian, Workman, Paul, Al-Lazikani, Bissan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550792/ https://www.ncbi.nlm.nih.gov/pubmed/34077750 http://dx.doi.org/10.1016/j.chembiol.2021.05.004 |
Ejemplares similares
-
The kinase polypharmacology landscape of clinical PARP inhibitors
por: Antolin, Albert A., et al.
Publicado: (2020) -
Polypharmacology in Precision Oncology: Current Applications and Future
Prospects
por: Antolin, Albert A., et al.
Publicado: (2016) -
Blocking the survival of the nastiest by HSP90 inhibition
por: Workman, Paul, et al.
Publicado: (2016) -
Objective, Quantitative, Data-Driven Assessment of Chemical Probes
por: Antolin, Albert A., et al.
Publicado: (2018) -
canSAR: update to the cancer translational research and drug discovery knowledgebase
por: Coker, Elizabeth A, et al.
Publicado: (2019)